Perrigo's Potential OTC Product Pipeline
This article was originally published in The Tan Sheet
You may also be interested in...
Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
OTC Allegra could soon face competition from private-label fexofenadine marketed by Perrigo, which acquired U.S. rights from ANDA-filer Teva.
Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
OTC Allegra could soon face competition from private-label fexofenadine marketed by Perrigo, which acquired U.S. rights from ANDA-filer Teva.
Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.